You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

VOTRIENT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Votrient patents expire, and what generic alternatives are available?

Votrient is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Votrient

A generic version of VOTRIENT was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VOTRIENT?
  • What are the global sales for VOTRIENT?
  • What is Average Wholesale Price for VOTRIENT?
Summary for VOTRIENT
Drug patent expirations by year for VOTRIENT
Drug Prices for VOTRIENT

See drug prices for VOTRIENT

Recent Clinical Trials for VOTRIENT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Medical Center GroningenPhase 4
Centre Leon BerardPhase 1/Phase 2
National Cancer Institute, FrancePhase 1/Phase 2

See all VOTRIENT clinical trials

US Patents and Regulatory Information for VOTRIENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VOTRIENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Subscribe ⤷  Subscribe
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Subscribe ⤷  Subscribe
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Subscribe ⤷  Subscribe
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Subscribe ⤷  Subscribe
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Subscribe ⤷  Subscribe
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VOTRIENT

See the table below for patents covering VOTRIENT around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1343782 COMPOSES CHIMIQUES (PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS) ⤷  Subscribe
Denmark 2311825 ⤷  Subscribe
Canada 2432000 PYRIMIDINEAMINES COMME MODULATEURS DE L'ANGIOGENESE (PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS) ⤷  Subscribe
Hong Kong 1059926 ⤷  Subscribe
Denmark 1343782 ⤷  Subscribe
Poland 363243 ⤷  Subscribe
Israel 156306 5 - ({4 - [(2,3 - DIMETHYL l - 2H - INDAZOL - 6 - YL)(METHYL) AMINO] PYRIMIDIN - 2 - YL} AMINO) - 2 - ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VOTRIENT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1343782 SPC025/2010 Ireland ⤷  Subscribe SPC025/2010: 20110401, EXPIRES: 20250613
1343782 10C0037 France ⤷  Subscribe PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614
1343782 C300456 Netherlands ⤷  Subscribe PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614
1343782 C01343782/01 Switzerland ⤷  Subscribe FORMER OWNER: GLAXOSMITHKLINE LLC, US
1343782 28/2010 Austria ⤷  Subscribe PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614
1343782 91710 Luxembourg ⤷  Subscribe 91710, EXPIRES: 20250614
1343782 SPC/GB10/032 United Kingdom ⤷  Subscribe PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

VOTRIENT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Votrient

Introduction to Votrient

Votrient, also known as pazopanib, is a protein-kinase inhibitor used in the treatment of advanced renal-cell carcinoma (RCC) and soft-tissue sarcoma. Developed by GlaxoSmithKline (GSK), it has been approved by regulatory bodies such as the FDA and the European Medicines Agency (EMA)[1][3].

Mechanism of Action

Votrient works by blocking specific enzymes known as protein kinases, which are involved in the growth and spread of cancer cells. These enzymes include VEGFR, PDGFR, and KIT, which are crucial for the formation of new blood vessels that tumors need to grow[1].

Clinical Efficacy

Clinical trials have shown that Votrient is more effective than placebo in treating advanced RCC and soft-tissue sarcoma. For RCC, patients treated with Votrient had a median progression-free survival (PFS) of 9.2 months, compared to 4.2 months for those receiving placebo. In the case of soft-tissue sarcoma, the median PFS was 20 weeks with Votrient versus seven weeks with placebo[1][3].

Regulatory Approval

Votrient received conditional marketing authorization from the European Commission in June 2010, which was later converted to full marketing authorization in July 2013 after additional evidence was provided. In the U.S., the FDA approved Votrient for advanced RCC in October 2009[1][3].

Market Segmentation

The global kidney cancer drugs market, which includes Votrient, is segmented by type, product, and end users. Votrient falls under the category of RCC treatments and competes with other drugs like Nexavar (Sorafenib), Sutent (Sunitinib), and Afinitor (Everolimus)[4].

Market Trends

The kidney cancer drugs market has experienced fluctuations due to various factors. The COVID-19 pandemic led to a decline in the market from $3.3 billion in 2020 to $3.29 billion in 2021, primarily due to the deferment of treatments for immunocompromised patients. However, the market is expected to recover and reach $3.6 billion by 2025, growing at a CAGR of 2.3%[4].

Competitive Landscape

Votrient faces significant competition from other targeted therapies and immune-oncology agents. Major players in the kidney cancer drugs market include Bayer AG, Pfizer Inc., Novartis International AG, Exelixis, Inc., and F. Hoffmann-La Roche AG. The increasing competition, especially from immune-oncology agents, has led to a decline in Votrient sales[2][5].

Financial Performance

Sales Decline

Votrient's sales have been declining due to increased competition. In the third quarter of 2023, Votrient sales dropped by 14% compared to the previous year, largely due to the rise of immune-oncology agents in metastatic treatments[2].

Revenue Figures

In the first quarter of 2023, Votrient generated $105 million in sales, which was a 19% decline compared to the same period in the previous year. This decline is consistent with the trend observed in the third quarter of 2023, where sales also dropped by 14%[5].

Impact on Company Financials

The decline in Votrient sales has had a noticeable impact on the financial performance of its parent company. While the overall net sales and core operating income of Novartis (which acquired GSK's oncology portfolio) have shown growth, the specific decline in Votrient sales has been a contributing factor to the challenges faced by the company in maintaining its market share in the oncology segment[2][5].

Future Outlook

Despite the current decline, Votrient remains a significant player in the treatment of advanced RCC and soft-tissue sarcoma. However, its market position is under pressure due to the emergence of new therapies and the evolving landscape of cancer treatment.

Market Recovery

The kidney cancer drugs market is expected to recover and grow modestly over the next few years. As the market adjusts to post-pandemic conditions and new treatments become available, Votrient may need to adapt to maintain its market share[4].

Strategic Considerations

To mitigate the impact of increased competition, GSK and its successors may need to focus on strategic marketing, expanding the drug's indications, or developing combination therapies that include Votrient. This could help in retaining and potentially growing the patient base.

Key Takeaways

  • Clinical Efficacy: Votrient has demonstrated significant efficacy in treating advanced RCC and soft-tissue sarcoma.
  • Regulatory Approval: It has received full marketing authorization in the EU and FDA approval in the U.S.
  • Market Trends: The kidney cancer drugs market is recovering from pandemic-related declines but faces intense competition.
  • Financial Performance: Votrient sales have declined due to increased competition from immune-oncology agents.
  • Future Outlook: The drug's market position is under pressure, but strategic adaptations could help in maintaining its relevance.

FAQs

What is Votrient used for?

Votrient is used to treat patients with advanced renal-cell carcinoma (RCC) and soft-tissue sarcoma.

How does Votrient work?

Votrient works by blocking specific protein kinases involved in the growth and spread of cancer cells.

What are the main competitors of Votrient?

Votrient competes with other targeted therapies such as Nexavar, Sutent, Afinitor, and immune-oncology agents.

Why have Votrient sales declined?

Votrient sales have declined due to increased competition from immune-oncology agents in metastatic treatments.

What is the future outlook for Votrient in the market?

The future outlook for Votrient is challenging due to competition, but strategic adaptations and market recovery could help in maintaining its market share.

Sources

  1. European Medicines Agency (EMA). Votrient | European Medicines Agency (EMA).
  2. Novartis. Novartis Q3 2023 Condensed Interim Financial Report.
  3. GlaxoSmithKline. FDA approves GlaxoSmithKline's Votrientâ„¢ for advanced renal cell cancer.
  4. GlobeNewswire. Kidney Cancer Drugs Industry Assessment and Recovery to 2030.
  5. Novartis. Novartis Q1 2023 Condensed Financial Report – Supplementary Data.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.